153 related articles for article (PubMed ID: 37448102)
1. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
2. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
4. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
Gallacher D; Kimani P; Stallard N
Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
[TBL] [Abstract][Full Text] [Related]
5. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Value Health; 2021 Nov; 24(11):1634-1642. PubMed ID: 34711364
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
van Oostrum I; Ouwens M; Remiro-Azócar A; Baio G; Postma MJ; Buskens E; Heeg B
Value Health; 2021 Sep; 24(9):1294-1301. PubMed ID: 34452709
[TBL] [Abstract][Full Text] [Related]
8. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
9. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
Che Z; Green N; Baio G
Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
[TBL] [Abstract][Full Text] [Related]
10. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
12. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
[TBL] [Abstract][Full Text] [Related]
13. Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study.
Gallacher D; Kimani P; Stallard N
Med Decis Making; 2021 May; 41(4):476-484. PubMed ID: 33626961
[TBL] [Abstract][Full Text] [Related]
14. Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation.
Cooney P; White A
Med Decis Making; 2023 Apr; 43(3):325-336. PubMed ID: 36647200
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Feb; ():. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
16. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
17. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models.
Andersson TM; Dickman PW; Eloranta S; Lambert PC
BMC Med Res Methodol; 2011 Jun; 11():96. PubMed ID: 21696598
[TBL] [Abstract][Full Text] [Related]
18. Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival.
Everest L; Blommaert S; Chu RW; Chan KKW; Parmar A
Value Health; 2022 Apr; 25(4):622-629. PubMed ID: 35365306
[TBL] [Abstract][Full Text] [Related]
19. How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
Kearns B; Stevens J; Ren S; Brennan A
Pharmacoeconomics; 2020 Feb; 38(2):193-204. PubMed ID: 31761997
[TBL] [Abstract][Full Text] [Related]
20. Survival extrapolation in the presence of cause specific hazards.
Benaglia T; Jackson CH; Sharples LD
Stat Med; 2015 Feb; 34(5):796-811. PubMed ID: 25413028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
